US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
US20050089958A1
(en)
*
|
1996-01-09 |
2005-04-28 |
Genentech, Inc. |
Apo-2 ligand
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
WO1997037020A1
(en)
|
1996-04-01 |
1997-10-09 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
US6136958A
(en)
*
|
1996-09-30 |
2000-10-24 |
Genentech, Inc. |
Antibodies to vertebrate smoothened proteins
|
US5990281A
(en)
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
ATE356212T1
(de)
|
1997-01-31 |
2007-03-15 |
Genentech Inc |
O-fukosyltransferase
|
JP2001510483A
(ja)
|
1997-06-13 |
2001-07-31 |
ジェネンテク,インコーポレイテッド |
タンパク質の回収
|
ATE393222T1
(de)
|
1997-09-18 |
2008-05-15 |
Genentech Inc |
Dcr3 polypeptid, ein tnfr homolog
|
ATE424459T1
(de)
|
1997-10-10 |
2009-03-15 |
Genentech Inc |
Apo-3 ligand
|
DE69840051D1
(de)
|
1997-10-29 |
2008-11-06 |
Genentech Inc |
Durch wnt-1 induzierbare gene
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
PT1481989E
(pt)
|
1997-11-21 |
2008-08-08 |
Genentech Inc |
Antigénios relacionados com a-33 e suas utilizações farmacológicas
|
JP2002505850A
(ja)
|
1997-12-03 |
2002-02-26 |
ジェネンテック・インコーポレーテッド |
ポリペプチド及び同じものをコードしている核酸
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
CA2318029C
(en)
|
1998-01-15 |
2009-05-19 |
Genentech, Inc. |
Apo-2 ligand
|
NZ508878A
(en)
|
1998-05-15 |
2003-08-29 |
Genentech Inc |
IL-17B and IL-17Cactive variants of IL-17 which stimulates epithelial, endothelial and fibroblastic cells
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
EP1484338B1
(en)
|
1998-12-22 |
2007-02-07 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
JP5456222B2
(ja)
|
1998-12-23 |
2014-03-26 |
ジェネンテック, インコーポレイテッド |
Il−1関連ポリペプチド
|
PL209786B1
(pl)
|
1999-01-15 |
2011-10-31 |
Genentech Inc |
Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
|
EP1953173B1
(en)
|
1999-06-15 |
2009-11-18 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids endoding the same
|
DE10084743T1
(de)
|
1999-06-25 |
2002-08-14 |
Genentech Inc |
Humanisierte Anti-ErbB2-Antikörper und Behandlung mit Anti-ErbB2-Antikörpern
|
TR200200472T2
(tr)
|
1999-08-27 |
2002-06-21 |
Genentech, Inc. |
Anti-Erb B2 antikorları ile tedavi için dozajlar
|
EP1686134A3
(en)
|
1999-12-01 |
2006-08-09 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
EP1897945B1
(en)
|
1999-12-23 |
2012-01-18 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
ATE424457T1
(de)
|
2000-01-13 |
2009-03-15 |
Genentech Inc |
Menschliche stra6 polypeptide
|
US6740520B2
(en)
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
EP2168980A1
(en)
|
2000-06-23 |
2010-03-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
|
EP2792747A1
(en)
|
2000-06-23 |
2014-10-22 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
ATE415978T1
(de)
|
2000-07-27 |
2008-12-15 |
Genentech Inc |
Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
ATE412009T1
(de)
|
2000-08-24 |
2008-11-15 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
SI1324776T2
(en)
|
2000-10-12 |
2018-06-29 |
Genentech, Inc. |
Concentrated protein formulations with reduced viscosity
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
US7727527B2
(en)
|
2001-05-30 |
2010-06-01 |
Genentech, Inc. |
Anti-NGF antibodies for the therapeutic treatments
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
CA2633413C
(en)
|
2001-06-20 |
2012-08-21 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
BR0212070A
(pt)
|
2001-08-29 |
2004-09-28 |
Genentech Inc |
ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
|
ATE516042T1
(de)
|
2001-09-18 |
2011-07-15 |
Genentech Inc |
Zusammensetzungen und verfahren zur behandlung und diagnose von tumoren
|
ES2624547T3
(es)
|
2001-11-14 |
2017-07-14 |
Janssen Biotech, Inc. |
Anticuerpos anti il 6, composiciones, métodos y usos
|
US20050171339A1
(en)
|
2001-12-28 |
2005-08-04 |
Izumi Sugo |
Method of stabilizing protein
|
EP2067472A1
(en)
|
2002-01-02 |
2009-06-10 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7452675B2
(en)
|
2002-01-25 |
2008-11-18 |
The Queen's Medical Center |
Methods of screening for TRPM4b modulators
|
EP2388265A1
(en)
|
2002-02-22 |
2011-11-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CA2477249A1
(en)
|
2002-02-25 |
2003-09-04 |
Genentech, Inc. |
Novel type-1 cytokine receptor glm-r
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
CA2490758C
(en)
|
2002-07-15 |
2014-09-23 |
Genentech, Inc. |
Dosage form of recombinant humanized monoclonal antibody 2c4
|
HUE033623T2
(en)
|
2002-09-11 |
2017-12-28 |
Genentech Inc |
protein purification
|
EP2116551A1
(en)
|
2002-09-11 |
2009-11-11 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP2444409A2
(en)
|
2002-09-16 |
2012-04-25 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
AU2003279084A1
(en)
|
2002-09-25 |
2004-04-19 |
Genentech, Inc. |
Novel compositions and methods for the treatment of psoriasis
|
EP2322200A3
(en)
|
2002-10-29 |
2011-07-27 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CA2503748A1
(en)
|
2002-11-08 |
2004-05-27 |
Genentech, Inc. |
Compositions and methods for the treatment of natural killer cell related diseases
|
WO2004047728A2
(en)
|
2002-11-26 |
2004-06-10 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2004058184A2
(en)
|
2002-12-24 |
2004-07-15 |
Rinat Neuroscience Corp. |
Anti-ngf antibodies and methods using same
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
KR101118340B1
(ko)
|
2003-03-12 |
2012-04-12 |
제넨테크, 인크. |
조혈을 촉진하기 위한 bv8 및(또는) eg-vegf의용도
|
CA2519241A1
(en)
|
2003-04-01 |
2004-11-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
MXPA05012723A
(es)
|
2003-05-30 |
2006-02-08 |
Genentech Inc |
Tratamiento con anticuerpos anti-vgf.
|
ES2538469T3
(es)
|
2003-06-05 |
2015-06-22 |
Genentech, Inc. |
Terapia de combinación para trastornos de células B
|
US8080382B2
(en)
|
2003-06-13 |
2011-12-20 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Monitoring immunologic, hematologic and inflammatory diseases
|
KR100835786B1
(ko)
|
2003-07-08 |
2008-06-09 |
제넨테크, 인크. |
Il-17a/f 이종 폴리펩티드 및 그의 치료 용도
|
SI1648940T1
(sl)
|
2003-07-28 |
2016-08-31 |
Genentech, Inc. |
Zmanjševanje izluževanja proteina A med afinitetno kromatografijo proteina A
|
WO2005014818A1
(ja)
|
2003-08-08 |
2005-02-17 |
Perseus Proteomics Inc. |
癌高発現遺伝子
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
CA2747871C
(en)
|
2003-11-17 |
2018-04-10 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US7750123B2
(en)
|
2003-11-25 |
2010-07-06 |
Dana Farber Cancer Institute, Inc. |
Antibodies against SARS-CoV and methods of use thereof
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
KR101195291B1
(ko)
|
2003-12-11 |
2012-10-26 |
제넨테크, 인크. |
C-met 이량체화 및 활성화를 억제하는 방법 및조성물
|
CA2551097A1
(en)
|
2003-12-23 |
2005-07-14 |
Rinat Neuroscience Corp. |
Agonist anti-trkc antibodies and methods using same
|
US20060122377A1
(en)
|
2004-02-19 |
2006-06-08 |
Genentech, Inc. |
CDR-repaired antibodies
|
EP3130349A1
(en)
|
2004-06-04 |
2017-02-15 |
Genentech, Inc. |
Method for treating multiple sclerosis
|
JP4947717B2
(ja)
|
2004-07-20 |
2012-06-06 |
ジェネンテック, インコーポレイテッド |
アンジオポエチン様4タンパク質のインヒビター、組み合わせ、およびそれらの使用
|
US7807165B2
(en)
|
2004-07-30 |
2010-10-05 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
DK1841793T3
(da)
|
2005-01-07 |
2010-07-19 |
Diadexus Inc |
Ovr110-antistofsammensætninger og fremgangsmåder til anvendelse deraf
|
CN102580084B
(zh)
|
2005-01-21 |
2016-11-23 |
健泰科生物技术公司 |
Her抗体的固定剂量给药
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
SI1850874T1
(sl)
|
2005-02-23 |
2014-01-31 |
Genentech, Inc. |
Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
|
EP1869184B1
(en)
|
2005-04-11 |
2011-09-28 |
National Research Council Of Canada |
Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87
|
WO2006119264A2
(en)
|
2005-04-29 |
2006-11-09 |
The Regents Of The University Of California |
Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
|
PE20061324A1
(es)
|
2005-04-29 |
2007-01-15 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, metodos y usos
|
EP2221316A1
(en)
|
2005-05-05 |
2010-08-25 |
Duke University |
Anti-CD19 antibody therapy for autoimmune disease
|
CA2608474C
(en)
|
2005-05-17 |
2019-11-12 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism
|
US7491391B2
(en)
|
2005-06-30 |
2009-02-17 |
Centocor, Inc. |
Anti-IL-23 antibodies, compositions, methods and uses
|
ES2526811T3
(es)
|
2005-08-10 |
2015-01-15 |
Macrogenics, Inc. |
Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos
|
ES2664854T3
(es)
|
2005-11-14 |
2018-04-23 |
Teva Pharmaceuticals International Gmbh |
Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina para tratar cefalea en racimos
|
WO2007065027A2
(en)
|
2005-12-02 |
2007-06-07 |
Dana Farber Cancer Institute |
Carbonic anhydrase ix (g250) antibodies and methods of use thereof
|
CA2631961A1
(en)
|
2005-12-02 |
2007-11-08 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling relating to antibodies that bind to il-22
|
EP1973948B1
(en)
|
2005-12-15 |
2015-02-11 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
ES2622602T3
(es)
|
2005-12-29 |
2017-07-06 |
Janssen Biotech, Inc. |
Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
|
ES2526204T3
(es)
|
2006-01-05 |
2015-01-08 |
Genentech, Inc. |
Anticuerpos anti-EphB4 y métodos para usar los mismos
|
US7803561B2
(en)
|
2006-02-06 |
2010-09-28 |
Rhode Island Hospital |
GPR30 estrogen receptor in breast cancers
|
EP2050335A1
(en)
|
2006-02-17 |
2009-04-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
EP1999148B8
(en)
|
2006-03-06 |
2014-03-05 |
Medlmmune, LLC |
Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US20100278821A1
(en)
|
2006-03-21 |
2010-11-04 |
The Regents Of The University Of California |
N-cadherin: target for cancer diagnosis and therapy
|
US20090130108A1
(en)
|
2006-03-21 |
2009-05-21 |
The Regents Of The University Of California |
N-Cadherin and Ly6 E: Targets for Cancer Diagnosis and Therapy
|
NZ571068A
(en)
|
2006-03-21 |
2012-06-29 |
Genentech Inc |
An antibody that can bind human alpha5beta1
|
CN101437536A
(zh)
|
2006-03-23 |
2009-05-20 |
诺华有限公司 |
抗肿瘤细胞抗原抗体治疗
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
NZ572178A
(en)
|
2006-05-04 |
2012-01-12 |
Genentech Inc |
Model systems and methods relating to zebrafish pro-apoptotic (zpa) polypeptides
|
TWI523864B
(zh)
|
2006-05-30 |
2016-03-01 |
建南德克公司 |
抗體及免疫接合物及其用途
|
AU2007297869A1
(en)
|
2006-06-01 |
2008-03-27 |
Genentech, Inc. |
Crystal structure of CRig and C3b: CRig complex
|
SG10201604649SA
(en)
|
2006-06-07 |
2016-07-28 |
Bioalliance Cv |
Antibodies Recognizing A Carbohydrate Containing Epitope On CD-43 And Cea Expressed On Cancer Cells And Methods Using Same
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
EP2037737B1
(en)
|
2006-07-11 |
2014-04-02 |
University Of Medicine And Dentistry Of New Jersey |
Cell membrane repair proteins, nucleic acids encoding the same and associated methods of use
|
CA2657934C
(en)
|
2006-07-19 |
2017-04-04 |
The Trustees Of The University Of Pennsylvania |
Wsx-1/p28 as a target for anti-inflammatory responses
|
US8586006B2
(en)
|
2006-08-09 |
2013-11-19 |
Institute For Systems Biology |
Organ-specific proteins and methods of their use
|
RU2009110154A
(ru)
|
2006-08-22 |
2010-09-27 |
Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) |
АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
|
EP2423332A1
(en)
|
2006-08-25 |
2012-02-29 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
CN101557818A
(zh)
|
2006-10-03 |
2009-10-14 |
新泽西医科和牙科大学 |
Atap肽、编码atap肽的核酸以及相关的应用方法
|
PT2061814E
(pt)
|
2006-10-27 |
2012-09-10 |
Genentech Inc |
Anticorpos e imunoconjugados e suas utilizações
|
AU2007353332B2
(en)
|
2006-11-21 |
2013-08-01 |
The Regents Of The University Of California |
Modulation of Rhamm (CD168) for selective adipose tissue development
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
BRPI0807635A2
(pt)
|
2007-02-22 |
2014-06-03 |
Genentech Inc |
Métodos para detecção de doença inflamatória intestinal
|
AU2008223069B2
(en)
|
2007-03-02 |
2012-12-13 |
F. Hoffmann-La Roche Ag |
Predicting response to a HER dimerisation inhibitor based on low HER3 expression
|
US20080279851A1
(en)
|
2007-05-07 |
2008-11-13 |
Medlmmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
US8546539B2
(en)
|
2007-05-14 |
2013-10-01 |
Novimmune S.A. |
Fc receptor-binding polypeptides with modified effector functions
|
CA2689302C
(en)
|
2007-06-08 |
2015-08-25 |
Australian Poultry Crc Pty Ltd. |
Clostridial toxin netb
|
EP2171090B1
(en)
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
DE17196350T1
(de)
|
2007-07-09 |
2018-12-27 |
Genentech, Inc. |
Verhindern der disulfid-bindungsreduktion während der rekombinanten herstellung von polypeptiden
|
PE20140625A1
(es)
|
2007-07-16 |
2014-05-29 |
Genentech Inc |
ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
|
EP2474557B1
(en)
|
2007-07-16 |
2014-08-20 |
Genentech, Inc. |
Anti-CD79b antibodies and immunoconjugates and methods of use
|
MX2010001307A
(es)
|
2007-08-02 |
2010-07-30 |
Novimmune Sa |
Anticuerpos anti-proteína regulada con la activación, expresada y secretada por los linfocitos t normales y metodos de uso de los mismos.
|
AU2008308761B2
(en)
|
2007-10-02 |
2014-10-16 |
Genentech, Inc. |
NLRR-1 antagonists and uses thereof
|
WO2011063161A2
(en)
|
2009-11-20 |
2011-05-26 |
The Regents Of The University Of California |
Epithelial membrane protein-2 (emp2) and proliferative vitreoretinopathy (pvr)
|
KR20160129099A
(ko)
|
2007-11-07 |
2016-11-08 |
제넨테크, 인크. |
미생물 질환의 치료를 위한 조성물 및 방법
|
MX2010005893A
(es)
|
2007-11-29 |
2011-03-04 |
Genentech Inc Star |
Marcadores de expresion genica para enfermedad inflamatoria de intestino.
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
CA2707483A1
(en)
|
2007-11-30 |
2009-06-11 |
Wolfgang Fraunhofer |
Protein formulations and methods of making same
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
EP3524619A1
(en)
|
2007-12-06 |
2019-08-14 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
KR101499278B1
(ko)
|
2007-12-17 |
2015-03-06 |
화이자 리미티드 |
간질성 방광염의 치료
|
JP5568478B2
(ja)
|
2007-12-18 |
2014-08-06 |
バイオアライアンス セー.フェー. |
癌細胞で発現するcd−43およびceaの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
|
CA2965198C
(en)
|
2008-01-15 |
2021-02-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
RU2553566C2
(ru)
|
2008-01-31 |
2015-06-20 |
Дженентек, Инк. |
АНТИ-CD79b АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
CA2719189C
(en)
|
2008-04-09 |
2020-08-04 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
BRPI0908665A2
(pt)
|
2008-05-16 |
2020-08-18 |
Genentech Inc |
método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
CA2736799A1
(en)
|
2008-08-25 |
2010-03-11 |
Burnham Institute For Medical Research |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
AU2009291747B2
(en)
|
2008-09-10 |
2016-05-26 |
Genentech, Inc. |
Methods for inhibiting ocular angiogenesis
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
TW201014605A
(en)
|
2008-09-16 |
2010-04-16 |
Genentech Inc |
Methods for treating progressive multiple sclerosis
|
CN102264763B
(zh)
|
2008-09-19 |
2016-04-27 |
米迪缪尼有限公司 |
定向于dll4的抗体及其用途
|
SG195558A1
(en)
|
2008-10-14 |
2013-12-30 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
BRPI0921845A2
(pt)
|
2008-11-12 |
2019-09-17 |
Medimmune Llc |
formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
|
JP2012512244A
(ja)
|
2008-12-16 |
2012-05-31 |
イー・エム・デイー・ミリポア・コーポレイシヨン |
タンパク質の精製
|
SG172219A1
(en)
|
2008-12-17 |
2011-07-28 |
Genentech Inc |
Hepatitis c virus combination therapy
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
CN102264759B
(zh)
|
2008-12-23 |
2016-05-11 |
弗·哈夫曼-拉罗切有限公司 |
与蛋白a的结合改变的免疫球蛋白变体
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
BRPI1006448B1
(pt)
|
2009-03-25 |
2021-08-17 |
Genentech, Inc |
Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, microorganismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
|
AU2010236787A1
(en)
|
2009-04-01 |
2011-11-10 |
Genentech, Inc. |
Anti-FcRH5 antibodies and immunoconjugates and methods of use
|
MX2011011729A
(es)
|
2009-05-05 |
2012-04-10 |
Novimmune Sa |
Anticuerpo anti il-17f y metodos de uso de los mismos.
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
MX2012000417A
(es)
|
2009-07-07 |
2012-02-08 |
Genentech Inc |
Diagnostico y tratamiento de enfermedades desmielinizantes autoinmunitarias.
|
EP2757160A3
(en)
|
2009-07-20 |
2014-07-30 |
Genentech, Inc. |
Gene expression markers for Crohn's disease
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
WO2011031397A1
(en)
|
2009-08-06 |
2011-03-17 |
Genentech, Inc. |
Method to improve virus removal in protein purification
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
KR20180114966A
(ko)
|
2009-08-11 |
2018-10-19 |
제넨테크, 인크. |
글루타민-비함유 세포 배양 배지에서의 단백질의 생성
|
US20110038871A1
(en)
|
2009-08-11 |
2011-02-17 |
Veena Viswanth |
Ccr2 inhibitors for treating conditions of the eye
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
MX2012002565A
(es)
|
2009-09-01 |
2012-05-29 |
Genentech Inc |
Purificacion de proteina mejorada a traves de una elucion de proteina a modificada.
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
US9096877B2
(en)
|
2009-10-07 |
2015-08-04 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
WO2011046515A1
(en)
|
2009-10-14 |
2011-04-21 |
Nanyang Technological University |
Antiproliferative agent
|
KR20120105446A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
|
EP2491059B1
(en)
|
2009-10-22 |
2015-02-25 |
F.Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods using same
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
US8361744B2
(en)
|
2009-11-05 |
2013-01-29 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
AR078986A1
(es)
|
2009-11-12 |
2011-12-14 |
Genentech Inc |
Un metodo para promover la densidad de espinas dendriticas
|
CA2992770A1
(en)
|
2009-11-24 |
2011-06-03 |
Medimmune Limited |
Targeted binding agents against b7-h1
|
NZ599707A
(en)
|
2009-11-30 |
2014-07-25 |
Genentech Inc |
Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211 = seqid2 )
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
CA2783846C
(en)
|
2009-12-21 |
2021-01-19 |
Genentech, Inc. |
Antibody formulation
|
AR079704A1
(es)
|
2009-12-23 |
2012-02-15 |
Genentech Inc |
Anticuerpos anti-bv8 y sus usos
|
DK2519542T3
(en)
|
2009-12-28 |
2019-01-14 |
Onco Therapy Science Inc |
ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
|
US20110159588A1
(en)
|
2009-12-30 |
2011-06-30 |
Kui Lin |
Methods for Modulating a PDGF-AA Mediated Biological Response
|
WO2011094759A2
(en)
|
2010-02-01 |
2011-08-04 |
The Regents Of The University Of California |
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
|
CN102933231B
(zh)
|
2010-02-10 |
2015-07-29 |
伊缪诺金公司 |
Cd20抗体及其用途
|
WO2011103490A2
(en)
|
2010-02-18 |
2011-08-25 |
The Regents Of The University Of California |
INTEGRIN αVβ8 NEUTRALIZING ANTIBODY
|
WO2011106297A2
(en)
|
2010-02-23 |
2011-09-01 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
SA114360064B1
(ar)
|
2010-02-24 |
2016-01-05 |
رينات نيوروساينس كوربوريشن |
طرق وأجسام مضادة معارضة ضد مستقبل il-7
|
BR112012022917A2
(pt)
|
2010-03-11 |
2017-01-10 |
Pfizer |
anticorpos com ligação a antígeno dependente de ph
|
BR112012024786A2
(pt)
|
2010-03-30 |
2017-01-10 |
Janssen Biotech Inc |
anticorpos humanizados il-25
|
CN107090045A
(zh)
|
2010-05-03 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
用于肿瘤诊断和治疗的组合物和方法
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
US8691918B2
(en)
|
2010-05-17 |
2014-04-08 |
Emd Millipore Corporation |
Stimulus responsive polymers for the purification of biomolecules
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
MY161534A
(en)
|
2010-05-25 |
2017-04-28 |
Genentech Inc |
Methods of purifying polypeptides
|
ES2599412T3
(es)
|
2010-05-28 |
2017-02-01 |
F. Hoffmann-La Roche Ag |
Disminución del nivel de lactato y aumento de la producción de polipéptidos regulando por disminución la expresión de la lactato deshidrogenasa y de la piruvato deshidrogenasa quinasa
|
CA2800531C
(en)
|
2010-06-02 |
2021-05-25 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
NZ602840A
(en)
|
2010-06-03 |
2014-11-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
US9315585B2
(en)
|
2010-06-19 |
2016-04-19 |
Memorial Sloan Kettering Cancer Center |
Anti-GD2 antibodies
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
WO2012021773A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1beta and il-18, for treatment of disease
|
PE20140190A1
(es)
|
2010-08-27 |
2014-02-10 |
Stem Centrx Inc |
Moduladores de proteinas notum y metodos de uso
|
EP2611465A4
(en)
|
2010-08-31 |
2014-06-04 |
Theraclone Sciences Inc |
NEUTRALIZING ANTI-VIRUS ANTIBODIES FOR HUMAN IMMUNODEFICIENCY (HIV)
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
US9458231B2
(en)
|
2010-09-03 |
2016-10-04 |
Stemcentrx, Inc. |
Modulators and methods of use
|
US8481680B2
(en)
|
2010-10-05 |
2013-07-09 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
WO2012099566A1
(en)
|
2010-11-17 |
2012-07-26 |
Sea Lane Biotechnologies, Llc |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
BR112013014321A2
(pt)
|
2010-12-08 |
2019-09-24 |
Stem Centrx Inc |
moduladores inovadores e métodos de uso
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
JP2014509591A
(ja)
|
2011-03-15 |
2014-04-21 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
JP6248029B2
(ja)
|
2011-03-31 |
2017-12-13 |
ジェネンテック, インコーポレイテッド |
ベータ7インテグリンアンタゴニストの投与方法
|
CA2831957A1
(en)
|
2011-04-07 |
2012-10-11 |
Amgen Inc. |
Novel egfr binding proteins
|
CA2837169C
(en)
|
2011-05-24 |
2021-11-09 |
Zyngenia, Inc. |
Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
|
EP2734546A1
(en)
|
2011-07-18 |
2014-05-28 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
DK2773438T4
(da)
|
2011-11-02 |
2022-01-03 |
Hoffmann La Roche |
Overladnings- og elueringskromatografi
|
CA2854233C
(en)
|
2011-11-04 |
2020-05-12 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
BR112014011331A2
(pt)
|
2011-11-11 |
2017-04-25 |
Rinat Neuroscience Corp |
anticorpos específicos para trop-2 e seus usos
|
IN2014CN04652A
(lt)
|
2011-12-22 |
2015-09-18 |
Rinat Neuroscience Corp |
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
EP2802601B1
(en)
|
2012-01-09 |
2019-11-13 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
EP2812443B1
(en)
|
2012-02-06 |
2019-05-29 |
Inhibrx, Inc. |
Cd47 antibodies and methods of use thereof
|
PE20150090A1
(es)
|
2012-02-24 |
2015-02-16 |
Stem Centrx Inc |
Moduladores y metodos de empleo novedosos referencia cruzada a solicitudes
|
HUE037613T2
(hu)
|
2012-03-29 |
2018-09-28 |
Novimmune Sa |
Anti-TLR4 antitestek és azok felhasználása
|
EP3511343A1
(en)
|
2012-05-04 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
EP2847230B1
(en)
|
2012-05-10 |
2020-08-12 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
TN2015000448A1
(en)
|
2012-06-11 |
2017-04-06 |
Amgen Inc |
Dual receptor antagonistic antigen-binding proteins and uses therof
|
EP2877494B1
(en)
|
2012-07-23 |
2020-07-15 |
La Jolla Institute for Allergy and Immunology |
Ptprs and proteoglycans in autoimmune disease
|
IN2015MN00139A
(lt)
|
2012-09-25 |
2015-10-16 |
Glenmark Pharmaceuticals Sa |
|
MX370848B
(es)
|
2012-10-04 |
2020-01-08 |
Dana Farber Cancer Inst Inc |
Anticuerpos monoclonales humanos anti-pd-l1 y métodos de uso.
|
BR112015007528A2
(pt)
|
2012-10-05 |
2018-09-04 |
Genentech Inc |
método para prever a resposta, para prever a responsividade, para identificar e para tratar um paciente que tem uma disfunção inflamatória gastrointestinal.
|
CA2890483A1
(en)
|
2012-11-09 |
2014-05-15 |
Robert ARCH |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
ES2784631T3
(es)
|
2012-12-03 |
2020-09-29 |
Novimmune Sa |
Anticuerpos anti-CD47 y métodos de uso de los mismos
|
SG11201506132PA
(en)
|
2013-02-06 |
2015-09-29 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
DK2958944T3
(da)
|
2013-02-22 |
2019-06-24 |
Abbvie Stemcentrx Llc |
Anti-dll3-antistof-pbd-konjugater og anvendelser deraf
|
SG10201913932VA
(en)
|
2013-03-13 |
2020-03-30 |
Genentech Inc |
Antibody formulations
|
PT2968466T
(pt)
|
2013-03-13 |
2018-10-22 |
Hoffmann La Roche |
Formulações de oxidação reduzida
|
WO2014160497A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Formulations with reduced oxidation
|
BR112015023752B1
(pt)
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
ES2798307T3
(es)
|
2013-03-15 |
2020-12-10 |
Hoffmann La Roche |
Composiciones de cultivo de células con antioxidantes y procedimientos para la producción de polipéptidos
|
CA2903576C
(en)
|
2013-03-15 |
2021-06-08 |
Nai-Kong V. Cheung |
High affinity anti-gd2 antibodies
|
JP6427552B2
(ja)
|
2013-03-15 |
2018-11-21 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
フラビウイルス中和抗体およびその使用方法
|
US9447193B2
(en)
|
2013-03-24 |
2016-09-20 |
Development Center For Biotechnology |
Methods for suppressing cancer by inhibition of TMCC3
|
WO2014160753A1
(en)
|
2013-03-27 |
2014-10-02 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
EP2986717A1
(en)
|
2013-04-19 |
2016-02-24 |
The Regents of The University of California |
Lone star virus
|
SG11201508264UA
(en)
|
2013-05-07 |
2015-11-27 |
Rinat Neuroscience Corp |
Anti-glucagon receptor antibodies and methods of use thereof
|
EP3019516B1
(en)
|
2013-07-12 |
2018-11-14 |
H. Hoffnabb-La Roche Ag |
Elucidation of ion exchange chromatography input optimization
|
KR20220042248A
(ko)
|
2013-07-16 |
2022-04-04 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
AU2014290361B2
(en)
|
2013-07-18 |
2019-04-18 |
Taurus Biosciences, Llc |
Humanized antibodies with ultralong complementarity determining regions
|
MX2016001854A
(es)
|
2013-08-12 |
2016-09-06 |
Genentech Inc |
Composiciones y metodo para tratar condiciones asociadas con el complemento.
|
EP3033356B1
(en)
|
2013-08-14 |
2020-01-15 |
Sachdev Sidhu |
Antibodies against frizzled proteins and methods of use thereof
|
AU2014312215B2
(en)
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
AU2014312310A1
(en)
|
2013-08-28 |
2016-04-07 |
Abbvie Stemcentrx Llc |
Novel SEZ6 modulators and methods of use
|
JP6736464B2
(ja)
|
2013-08-29 |
2020-08-05 |
シティ・オブ・ホープCity of Hope |
細胞透過性コンジュゲート及びその使用の方法
|
CA2925310C
(en)
|
2013-09-27 |
2022-12-06 |
Genentech, Inc. |
Anti-pdl1 antibody formulations
|
JP2016538275A
(ja)
|
2013-11-04 |
2016-12-08 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
T細胞再標的化ヘテロ二量体免疫グロブリン(hetero−dimeric immunoglobulin)の製造
|
BR112016009797A2
(pt)
|
2013-11-13 |
2017-12-05 |
Bristol Myers Squibb Co |
anticorpos específicos de ligante 1a do tipo fator de necrose tumoral e composições e usos dos mesmos
|
JP6667437B2
(ja)
|
2013-12-02 |
2020-03-18 |
ベイラー カレッジ オブ メディスンBaylor College Of Medicine |
最適な体重及び血糖を維持するための新規ポリペプチドホルモンの同定
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3083686B2
(en)
|
2013-12-17 |
2023-03-22 |
F. Hoffmann-La Roche AG |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
RU2016128726A
(ru)
|
2013-12-17 |
2018-01-23 |
Дженентек, Инк. |
Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20
|
EP4043493A1
(en)
|
2013-12-24 |
2022-08-17 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
ES2694857T3
(es)
|
2014-02-04 |
2018-12-27 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
US20170174751A1
(en)
|
2014-03-19 |
2017-06-22 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
SI3119431T1
(sl)
|
2014-03-21 |
2024-06-28 |
Teva Pharmaceuticals International Gmbh |
Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
|
AR099856A1
(es)
|
2014-03-27 |
2016-08-24 |
Genentech Inc |
Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
|
WO2015161267A2
(en)
|
2014-04-18 |
2015-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to cd99
|
JP6691872B2
(ja)
|
2014-05-30 |
2020-05-13 |
ヘンリクス バイオテック カンパニー リミテッド |
抗上皮増殖因子受容体(egfr)抗体
|
PL3157561T3
(pl)
|
2014-06-17 |
2020-06-29 |
Medimmune Limited |
Ulepszone przeciwciała alfa-v beta-8
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
EP3201232A1
(en)
|
2014-10-03 |
2017-08-09 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
JP6795505B2
(ja)
|
2014-10-06 |
2020-12-02 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
ヒト化ccケモカイン受容体4(ccr4)抗体およびその使用法
|
AU2015342964B2
(en)
|
2014-11-05 |
2021-06-24 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
CA2966558C
(en)
|
2014-11-05 |
2024-03-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
SG11201703605QA
(en)
|
2014-11-17 |
2017-06-29 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
EP3733696A1
(en)
|
2015-01-13 |
2020-11-04 |
City of Hope |
Ctla4-binding protein peptide-linker masks
|
CA2972986A1
(en)
|
2015-01-16 |
2016-07-21 |
City Of Hope |
Cell penetrating antibodies
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
AR103782A1
(es)
|
2015-02-26 |
2017-05-31 |
Genentech Inc |
ANTAGONISTAS DE INTEGRINA b7 Y MÉTODOS DE TRATAMIENTO DE LA ENFERMEDAD DE CROHN
|
SG10201913158PA
(en)
|
2015-04-03 |
2020-02-27 |
Eureka Therapeutics Inc |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
WO2016164835A1
(en)
|
2015-04-08 |
2016-10-13 |
Dana-Farber Cancer Institute, Inc. |
Humanized influenza monoclonal antibodies and methods of use thereof
|
PL3283106T3
(pl)
|
2015-04-13 |
2022-05-02 |
Pfizer Inc. |
Przeciwciała terapeutyczne i ich zastosowania
|
AU2016258742B9
(en)
|
2015-05-01 |
2023-07-13 |
Dana-Farber Cancer Institute, Inc. |
Methods of mediating cytokine expression with anti CCR4 antibodies
|
EP3447075B1
(en)
|
2015-05-15 |
2023-08-09 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
PL3294764T3
(pl)
|
2015-05-15 |
2021-06-28 |
City Of Hope |
Kompozycje chimerycznego receptora antygenowego
|
AR105618A1
(es)
|
2015-05-29 |
2017-10-25 |
Genentech Inc |
Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
JP6896650B2
(ja)
|
2015-06-17 |
2021-06-30 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法
|
MX2017016647A
(es)
|
2015-06-24 |
2019-04-25 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista.
|
US11066481B2
(en)
|
2015-07-23 |
2021-07-20 |
The Regents Of The University Of California |
Antibodies to coagulation factor XIa and uses thereof
|
EP3331543A4
(en)
|
2015-08-06 |
2019-03-20 |
City of Hope |
CONJUGATES OF CELL PENETRATION FORMED OF PROTEIN AND ANTIBODIES AND METHODS OF USE
|
WO2017041004A1
(en)
|
2015-09-02 |
2017-03-09 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for modulating t-cell mediated immune response
|
KR20180075537A
(ko)
|
2015-10-06 |
2018-07-04 |
제넨테크, 인크. |
다발성 경화증을 치료하기 위한 방법
|
EP3365369A1
(en)
|
2015-10-23 |
2018-08-29 |
Pfizer Inc |
Anti-il-2 antibodies and compositions and uses thereof
|
CA3007997A1
(en)
|
2015-12-10 |
2017-06-15 |
City Of Hope |
Cell penetrating cyanine-coupled antibodies
|
CA3009527C
(en)
|
2015-12-24 |
2024-01-09 |
Stephen WILLINGHAM |
Methods of treating cancer
|
EP3397243A1
(en)
|
2015-12-30 |
2018-11-07 |
H. Hoffnabb-La Roche Ag |
Use of tryptophan derivatives for protein formulations
|
CA3007419A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
WO2017125831A1
(en)
|
2016-01-21 |
2017-07-27 |
Pfizer Inc. |
Mono and bispecific antibodies for epidermal growth factor receptor variant iii and cd3 and their uses
|
JP7438662B2
(ja)
|
2016-01-25 |
2024-02-27 |
ジェネンテック, インコーポレイテッド |
T細胞依存性二重特異的抗体をアッセイするための方法
|
CA3019952A1
(en)
|
2016-02-04 |
2017-08-10 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
MX2018009800A
(es)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anticuerpos y fragmentos anti-vista, usos de los mismos y procedimientos de identificacion de los mismos.
|
JP7468992B2
(ja)
|
2016-03-29 |
2024-04-16 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置
|
US10836720B2
(en)
|
2016-04-01 |
2020-11-17 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 5 beta 1 and methods of use
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
WO2017196902A2
(en)
|
2016-05-10 |
2017-11-16 |
Genentech, Inc. |
Methods of decreasing trisulfide bonds during recombinant production of polypeptides
|
EP3472177B1
(en)
|
2016-06-17 |
2024-08-14 |
F. Hoffmann-La Roche AG |
Purification of multispecific antibodies
|
JP7082967B2
(ja)
|
2016-07-22 |
2022-06-09 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
グルココルチコイド誘導性腫瘍壊死因子受容体(gitr)抗体及びその使用方法
|
CN106079858B
(zh)
*
|
2016-08-03 |
2017-05-17 |
钟晴晴 |
一种丝网印刷机
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
CN109716127B
(zh)
|
2016-08-15 |
2022-06-14 |
豪夫迈·罗氏有限公司 |
定量包含非离子表面活性剂和多肽的组合物中非离子表面活性剂的层析方法
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
EP3509633A1
(en)
|
2016-09-06 |
2019-07-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating or preventing zika virus infection
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
EP4339615A3
(en)
|
2016-09-16 |
2024-05-22 |
Shanghai Henlius Biotech, Inc. |
Anti-pd-1 antibodies
|
US20180111984A1
(en)
|
2016-09-23 |
2018-04-26 |
Teva Pharmaceuticals International Gmbh |
Treating cluster headache
|
CN109952314A
(zh)
|
2016-09-23 |
2019-06-28 |
泰瓦制药国际有限公司 |
治疗难治性偏头痛
|
AU2017335991B2
(en)
|
2016-09-29 |
2023-07-06 |
The Regents Of The University Of California |
Neutralizing antibodies to the αVβ8 integrin complex for immunotherapy
|
KR20240046648A
(ko)
|
2016-09-30 |
2024-04-09 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 안전하고 효과적인 방법
|
EP3535299A1
(en)
|
2016-11-04 |
2019-09-11 |
Novimmune S.A. |
Anti-cd19 antibodies and methods of use thereof
|
EP3538101B1
(en)
|
2016-11-14 |
2024-06-19 |
Virginia Commonwealth University |
Inhibitors of cancer and/or metastasis
|
KR20240065333A
(ko)
|
2016-11-16 |
2024-05-14 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 방법
|
TW201825515A
(zh)
|
2017-01-04 |
2018-07-16 |
美商伊繆諾金公司 |
Met抗體以及其免疫結合物及用途
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
JP2020510435A
(ja)
|
2017-03-03 |
2020-04-09 |
ライナット ニューロサイエンス コーポレイション |
抗gitr抗体およびその使用方法
|
EP3609915A1
(en)
|
2017-04-12 |
2020-02-19 |
Pfizer Inc |
Antibodies having conditional affinity and methods of use thereof
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
EP4230649A3
(en)
|
2017-04-25 |
2023-10-25 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2018215835A1
(en)
|
2017-05-26 |
2018-11-29 |
Novimmune Sa |
Anti-cd47 x anti-mesothelin antibodies and methods of use thereof
|
US11421040B2
(en)
|
2017-06-02 |
2022-08-23 |
Pfizer Inc. |
Antibodies specific for FLT3 and their uses
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
KR20200115596A
(ko)
|
2018-02-01 |
2020-10-07 |
화이자 인코포레이티드 |
Cd70에 특이적인 항체 및 이의 용도
|
IL276896B2
(en)
|
2018-03-05 |
2024-06-01 |
Janssen Biotech Inc |
Methods for treating Crohn's disease with a specific anti-IL23 antibody
|
US11597727B2
(en)
|
2018-03-13 |
2023-03-07 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 2 beta 1 and methods of use
|
AU2019235523A1
(en)
|
2018-03-14 |
2020-10-29 |
Novimmune Sa |
Anti-CD3 epsilon antibodies and methods of use thereof
|
CN108357203A
(zh)
*
|
2018-04-23 |
2018-08-03 |
广州市威顿彩印有限公司 |
一种彩印产线用转叶式干燥设备及其使用方法
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
US20190345245A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
CN113286634A
(zh)
|
2018-05-23 |
2021-08-20 |
辉瑞公司 |
对gucy2c特异性的抗体及其用途
|
WO2019224385A2
(en)
|
2018-05-24 |
2019-11-28 |
Glenmark Pharmaceuticals S.A. |
Combined bispecific antibody and immuno-oncology therapies
|
EA202190092A1
(ru)
|
2018-06-21 |
2021-05-18 |
Юманити Терапьютикс, Инк. |
Композиции и способы лечения и профилактики неврологических расстройств
|
US20200030443A1
(en)
|
2018-06-23 |
2020-01-30 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
CN112638478A
(zh)
|
2018-06-29 |
2021-04-09 |
希望之城公司 |
用于治疗某些自身免疫病症的cd6靶向性嵌合抗原受体
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
CN112839644A
(zh)
|
2018-07-18 |
2021-05-25 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂、抗代谢物和铂剂治疗肺癌的方法
|
EP3824295A4
(en)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
PREDICTORS OF PROLONGED RESPONSE AFTER TREATMENT WITH AN ANTI-IL23 SPECIFIC ANTIBODY
|
AR115925A1
(es)
|
2018-08-08 |
2021-03-10 |
Genentech Inc |
Uso de derivados de triptófano y l-metionina para formulación de proteínas
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
JP2022501388A
(ja)
|
2018-09-19 |
2022-01-06 |
ラホヤ インスティチュート フォー イミュノロジー |
関節リウマチにおけるptprs及びプロテオグリカン
|
EP4249917A3
(en)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
EP3877407A1
(en)
|
2018-11-05 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Methods of producing two chain proteins in prokaryotic host cells
|
BR112021009287A2
(pt)
|
2018-11-20 |
2021-10-26 |
Janssen Biotech, Inc. |
Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
|
US20220143094A1
(en)
|
2019-04-19 |
2022-05-12 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
JP2022534020A
(ja)
|
2019-05-23 |
2022-07-27 |
ヤンセン バイオテツク,インコーポレーテツド |
Il-23及びtnfアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
|
WO2020245677A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
TW202112799A
(zh)
|
2019-06-05 |
2021-04-01 |
美商建南德克公司 |
過載層析管柱之再生方法
|
JPWO2021010326A1
(lt)
|
2019-07-12 |
2021-01-21 |
|
|
EP4004037A1
(en)
|
2019-07-26 |
2022-06-01 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
TW202120551A
(zh)
|
2019-08-12 |
2021-06-01 |
美商普瑞諾生物科技公司 |
藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
US20230076643A1
(en)
|
2019-12-30 |
2023-03-09 |
City Of Hope |
Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
|
KR20220140568A
(ko)
|
2020-02-11 |
2022-10-18 |
벤더르빌트 유니버시티 |
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
|
PT4045533T
(pt)
|
2020-03-26 |
2024-02-14 |
Univ Vanderbilt |
Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
US11634477B2
(en)
|
2020-04-28 |
2023-04-25 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies and methods of use thereof
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
JP2023533793A
(ja)
|
2020-07-17 |
2023-08-04 |
ファイザー・インク |
治療用抗体およびそれらの使用
|
EP4240758A1
(en)
|
2020-11-04 |
2023-09-13 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
JP2024505636A
(ja)
|
2021-01-15 |
2024-02-07 |
ザ ロックフェラー ユニバーシティー |
抗sars-cov-2中和抗体
|
TW202244060A
(zh)
|
2021-01-20 |
2022-11-16 |
美商昂科里斯龐司公司 |
免疫調節抗體及其用途
|
KR20230156387A
(ko)
|
2021-03-12 |
2023-11-14 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체에 의해 건선성 관절염을 치료하는 안전하고 효과적인 방법
|
MX2023010697A
(es)
|
2021-03-12 |
2023-11-23 |
Janssen Biotech Inc |
Método para tratar pacientes con artritis psoriásica con respuesta inadecuada a la terapia de tnf con anticuerpo específico anti-il23.
|
CA3212599A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
US20220315655A1
(en)
|
2021-03-22 |
2022-10-06 |
Novimmune Sa |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
IL312538A
(en)
|
2021-11-05 |
2024-07-01 |
Abviro Llc |
Broadly reactive human monoclonal influenza antibodies and methods for their use
|
CA3238377A1
(en)
|
2021-11-15 |
2023-05-19 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
CN114485122A
(zh)
*
|
2022-02-24 |
2022-05-13 |
广西青松木业有限公司 |
一种隧道式木材单板烘干生产线
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
US20240254234A1
(en)
|
2022-10-21 |
2024-08-01 |
Novimmune Sa |
PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
WO2024110898A1
(en)
|
2022-11-22 |
2024-05-30 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
WO2024173607A2
(en)
|
2023-02-14 |
2024-08-22 |
Evolveimmune Therapeutics, Inc. |
Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
|